CoChat
Sign Up
Cited by 9

Circulating tumor DNA and tissue complementarily detect genomic alterations in metastatic hormone-sensitive prostate cancer

Yang, Bin, Zhao, Tingting, Dong, Baijun, Chen, Wei, Yang, Guanjie, Xie, Jun, Guo, Changcheng, Wang, Ruiliang +5 more·2024·iScience
DOI 10.1016/j.isci.2024.108931PMC PMC10847732
Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.isci.2024.108931

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In metastatic hormone-sensitive disease, paired analyses of tissue and ctDNA have identified partially distinct genomic alterations and shown that integrated profiling improves detection of features associated with progression to castration resistance.

    “In metastatic hormone-sensitive disease, paired analyses of tissue and ctDNA have identified partially distinct genomic alterations and shown that integrated profiling improves detection of features associated with progression to castration resistance [18].”

    From A decision-oriented framework for genomic testing across the prostate cancer continuum (2026) · cites this paper as [18]

    Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured

  • Germline, somatic, and liquid biopsy-based approaches are increasingly indispensable in advanced disease, particularly when they identify actionable alterations such as HRD or dMMR.

    “In contrast, germline, somatic, and liquid biopsy–based approaches are increasingly indispensable in advanced disease, particularly when they identify actionable alterations such as homologous recombination repair deficiency or mismatch repair deficiency [8–10, 18].”

    From A decision-oriented framework for genomic testing across the prostate cancer continuum (2026) · cites this paper as [18]

    The Introduction links DNA-repair defects and mismatch-repair deficiency to treatment options in advanced cancer, and the Discussion describes tissue and ctDNA profiling as complementary ways to detect clinically relevant alterations. But the Discussion presents ctDNA’s routine clinical use as a future prospect, not an indispensable approach, and the paper does not establish that germline testing is indispensable. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

  • Contemporary studies demonstrate that ctDNA can complement tissue sequencing, identify non-overlapping clinically relevant alterations, and capture dynamic tumor evolution during treatment.

    “Contemporary studies demonstrate that circulating tumor DNA (ctDNA) can complement tissue sequencing, identify non-overlapping clinically relevant alterations, and capture dynamic tumor evolution during treatment [18, 19].”

    From A decision-oriented framework for genomic testing across the prostate cancer continuum (2026) · cites this paper as [18]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 30

  1. [1]Boyd L.K. Mao X. Lu Y.-J. The complexity of prostate cancer: genomic alterations and heterogeneity Nat. Rev. Urol. 9 2012 652 664 10.1038/nrurol.2012.185 23132303 · DOI
  2. [2]Sung H. Ferlay J. Siegel R.L. Laversanne M. Soerjomataram I. Jemal A. Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries CA Cancer J. Clin. 71 2021 209 249 10.3322/caac.21660 33538338 · DOI · Paper page
  3. [3]Dong B. Fan L. Yang B. Chen W. Li Y. Wu K. Zhang F. Dong H. Cheng H. Pan J. Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study J. Natl. Compr. Cancer Netw. 19 2021 905 914 10.6004/jnccn.2020.7663 33990090 · DOI
  4. [4]Robinson D. Van Allen E.M. Wu Y.-M. Schultz N. Lonigro R.J. Mosquera J.-M. Montgomery B. Taplin M.-E. Pritchard C.C. Attard G. Integrative clinical genomics of advanced prostate cancer Cell 161 2015 1215 1228 10.1016/j.cell.2015.05.001 26000489 PMC4484602 · DOI · Paper page
  5. [5]Abida W. Armenia J. Gopalan A. Brennan R. Walsh M. Barron D. Danila D. Rathkopf D. Morris M. Slovin S. Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making JCO Precis. Oncol. 2017 2017 1 16 10.1200/PO.17.00029 PMC5558263 28825054 · DOI · Paper page
  6. [6]Van Dessel L.F. Van Riet J. Smits M. Zhu Y. Hamberg P. Van Der Heijden M.S. Bergman A.M. Van Oort I.M. De Wit R. Voest E.E. The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact Nat. Commun. 10 2019 5251 10.1038/s41467-019-13084-7 31748536 PMC6868175 · DOI
  7. [7]Fan L. Fei X. Zhu Y. Chi C. Pan J. Sha J. Xin Z. Gong Y. Du X. Wang Y. Distinct Response to Platinum-Based Chemotherapy among Patients with Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination J. Urol. 206 2021 630 637 10.1097/JU.0000000000001819 33904759 · DOI
  8. [8]Abida W. Patnaik A. Campbell D. Shapiro J. Bryce A.H. McDermott R. Sautois B. Vogelzang N.J. Bambury R.M. Voog E. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration J. Clin. Oncol. 38 2020 3763 3772 10.1200/JCO.20.01035 32795228 PMC7655021 · DOI · Paper page
  9. [9]De Bono J. Mateo J. Fizazi K. Saad F. Shore N. Sandhu S. Chi K.N. Sartor O. Agarwal N. Olmos D. Olaparib for Metastatic Castration-Resistant Prostate Cancer N. Engl. J. Med. 382 2020 2091 2102 10.1056/NEJMoa1911440 32343890 · DOI · Paper page
  10. [10]Mota J.M. Barnett E. Nauseef J.T. Nguyen B. Stopsack K.H. Wibmer A. Flynn J.R. Heller G. Danila D.C. Rathkopf D. Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations JCO Precis. Oncol. 4 2020 355 366 10.1200/po.19.00346 32856010 PMC7446522 · DOI
  11. [11]Le D.T. Durham J.N. Smith K.N. Wang H. Bartlett B.R. Aulakh L.K. Lu S. Kemberling H. Wilt C. Luber B.S. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade Science 357 2017 409 413 10.1126/science.aan6733 28596308 PMC5576142 · DOI · Paper page
  12. [12]Hamid A.A. Gray K.P. Shaw G. MacConaill L.E. Evan C. Bernard B. Loda M. Corcoran N.M. Van Allen E.M. Choudhury A.D. Sweeney C.J. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer Eur. Urol. 76 2019 89 97 10.1016/j.eururo.2018.11.045 30553611 · DOI
  13. [13]Abida W. Cyrta J. Heller G. Prandi D. Armenia J. Coleman I. Cieslik M. Benelli M. Robinson D. Van Allen E.M. Genomic correlates of clinical outcome in advanced prostate cancer Proc. Natl. Acad. Sci. USA 116 2019 11428 11436 10.1073/pnas.1902651116 31061129 PMC6561293 · DOI · Paper page
  14. [14]Stopsack K.H. Nandakumar S. Wibmer A.G. Haywood S. Weg E.S. Barnett E.S. Kim C.J. Carbone E.A. Vasselman S.E. Nguyen B. Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer Clin. Cancer Res. 26 2020 3230 3238 10.1158/1078-0432.CCR-20-0168 32220891 PMC7334067 · DOI
  15. [15]Maia M.C. Salgia M. Pal S.K. Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers Nat. Rev. Urol. 17 2020 271 291 10.1038/s41585-020-0297-9 32203306 · DOI
  16. [16]Beltran H. Romanel A. Conteduca V. Casiraghi N. Sigouros M. Franceschini G.M. Orlando F. Fedrizzi T. Ku S.-Y. Dann E. Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer J. Clin. Invest. 130 2020 1653 1668 10.1172/JCI131041 32091413 PMC7108892 · DOI
  17. [17]Romanel A. Gasi Tandefelt D. Conteduca V. Jayaram A. Casiraghi N. Wetterskog D. Salvi S. Amadori D. Zafeiriou Z. Rescigno P. Plasma AR and abiraterone-resistant prostate cancer Sci. Transl. Med. 7 2015 312re10 10.1126/scitranslmed.aac9511 PMC6112410 26537258 · DOI
  18. [18]Annala M. Vandekerkhove G. Khalaf D. Taavitsainen S. Beja K. Warner E.W. Sunderland K. Kollmannsberger C. Eigl B.J. Finch D. Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer Cancer Discov. 8 2018 444 457 10.1158/2159-8290.CD-17-0937 29367197 · DOI
  19. [19]Wyatt A.W. Annala M. Aggarwal R. Beja K. Feng F. Youngren J. Foye A. Lloyd P. Nykter M. Beer T.M. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer J. Natl. Cancer Inst. 109 2017 djx118 10.1093/jnci/djx118 PMC6440274 29206995 · DOI
  20. [20]Lau E. McCoy P. Reeves F. Chow K. Clarkson M. Kwan E.M. Packwood K. Northen H. He M. Kingsbury Z. Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression Genome Med. 12 2020 72 10.1186/s13073-020-00770-1 32807235 PMC7430029 · DOI
  21. [21]Hennigan S.T. Trostel S.Y. Terrigino N.T. Voznesensky O.S. Schaefer R.J. Whitlock N.C. Wilkinson S. Carrabba N.V. Atway R. Shema S. Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer JCO Precis. Oncol. 3 2019 1 13 10.1200/PO.19.00176 PMC6746181 31528835 · DOI
  22. [22]Wang R. Xu Q. Guo H. Yang G. Zhang J. Wang H. Xu T. Guo C. Yuan J. He Y. Concordance and Clinical Significance of Genomic Alterations in Progressive Tumor Tissue and Matched Circulating Tumor DNA in Aggressive-variant Prostate Cancer Cancer Res. Commun. 3 2023 2221 2232 10.1158/2767-9764.CRC-23-0175 37877742 PMC10624154 · DOI
  23. [23]Vandekerkhove G. Struss W.J. Annala M. Kallio H.M.L. Khalaf D. Warner E.W. Herberts C. Ritch E. Beja K. Loktionova Y. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer Eur. Urol. 75 2019 667 675 10.1016/j.eururo.2018.12.042 30638634 · DOI
  24. [24]Schweizer M.T. Ha G. Gulati R. Brown L.C. McKay R.R. Dorff T. Hoge A.C.H. Reichel J. Vats P. Kilari D. CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade JCO Precis. Oncol. 4 2020 382 392 10.1200/PO.19.00383 32671317 PMC7363399 · DOI
  25. [25]Messina C. Cattrini C. Soldato D. Vallome G. Caffo O. Castro E. Olmos D. Boccardo F. Zanardi E. BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications JAMA Oncol. 2020 2020 4986365 10.1155/2020/4986365 PMC7492871 32963528 · DOI
  26. [26]Kyriakopoulos C.E. Chen Y.-H. Carducci M.A. Liu G. Jarrard D.F. Hahn N.M. Shevrin D.H. Dreicer R. Hussain M. Eisenberger M. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial J. Clin. Oncol. 36 2018 1080 1087 10.1200/JCO.2017.75.3657 29384722 PMC5891129 · DOI
  27. [27]Bolger A.M. Lohse M. Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data Bioinforma. Oxf. Engl. 30 2014 2114 2120 10.1093/bioinformatics/btu170 PMC4103590 24695404 · DOI · Paper page
  28. [28]Li H. Durbin R. Fast and accurate short read alignment with Burrows–Wheeler transform Bioinformatics 25 2009 1754 1760 10.1093/bioinformatics/btp324 19451168 PMC2705234 · DOI · Paper page
  29. [29]McKenna A. Hanna M. Banks E. Sivachenko A. Cibulskis K. Kernytsky A. Garimella K. Altshuler D. Gabriel S. Daly M. DePristo M.A. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data Genome Res. 20 2010 1297 1303 10.1101/gr.107524.110 20644199 PMC2928508 · DOI · Paper page
  30. [30]Wang K. Li M. Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data Nucleic Acids Res. 38 2010 e164 10.1093/nar/gkq603 20601685 PMC2938201 · DOI

Cited by

Sorted by citations

Authors
Yang, B., Zhao, T., Dong, B., Chen, W., Yang, G., Xie, J., Guo, C., Wang, R., Wang, H., Huang, L., Peng, B., Xue, W., & Yao, X.
ORCID
Yang, Bin
Venue
iScience
Publisher
Elsevier BV
Published
2024-02
Volume
27
Issue
2
Pages
108931
ISSN
2589-0042
DOI
10.1016/j.isci.2024.108931
PMC
PMC10847732
Cited by
9
References
0
Language
en
Licence
Funders
  • Shanghai Municipal Health Commission
  • National Natural Science Foundation of China

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review